SGM
CAPR icon

Seven Grand Managers’s Capricor Therapeutics CAPR Stock Holding History

Seven Grand Managers’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$602K Sell
25,000
-75,000
-75% -$2.27M 0.02% 170
2026
Q1 		$3.04M Hold
100,000
– – 0.2% 96
2025
Q4 		$2.89M Buy
+100,000
New +$1.31M 0.22% 97

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Seven Grand Managers's CAPR Position: Q2 2026 in Review

Seven Grand Managers reduced its Capricor Therapeutics (CAPR) stake by 75% in Q2 2026, selling an estimated $2.27M and leaving 25,000 shares worth $602K. The position accounts for 0.02% of the portfolio, ranked #170.

Seven Grand Managers first reported a position in CAPR in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.04M in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Seven Grand Managers held 25,000 shares of Capricor Therapeutics worth $602K as of Q2 2026.
  • Seven Grand Managers sold 75,000 Capricor Therapeutics shares in Q2 2026, an estimated $2.27M.
  • Capricor Therapeutics made up 0.02% of Seven Grand Managers's portfolio in Q2 2026, its #170 holding.
  • Seven Grand Managers first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Seven Grand Managers's Capricor Therapeutics position peaked at $3.04M in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.